NBTX
NASDAQ
$35.73
Nanobiotix (NBTX)
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $43.86 (+22.75%)
Market Cap
$1.91B
Revenue 5Y CAGR
+31.49%
Free Cash Flow Yield
-3.24%
Beta (5Y)
1.10
Price Chart
Valuation
Market Cap$1.91B
Forward P/E102.04
P/S62.26
P/B65.02
Profitability
Total Revenue (TTM)$26M
Gross Profit (TTM)$38M
EBITDA-$93M
Profit Margin-73.5%
Operating Margin-196.4%
EPS-$2.15
Financial Health
Debt-to-Equity-112.8%
Free Cash Flow Yield-3.24%
Growth & Risk
EPS 5Y CAGR-5.64%
Revenue 5Y CAGR+31.49%
FCF 5Y CAGR-1.09%
Beta (5Y)1.10
Sharpe Ratio2.26